Overall death rates for the two groups were the same, though the aspirin group's nonfatal heart-attack rate was much lower.
"Physicians, will, for a time, be forced to make their professional judgments about aspirin use on the basis of incomplete information," said the FDA commentary, co-written by agency Director Dr. Frank E. Young.
 Doctors should be cautious in prescribing aspirin as a preventer of heart attacks until more research supports its value, the Food and Drug Administration said.
Taking aspirin to prevent heart attacks may increase some people's chances of dying of other things, especially hemorrhagic strokes, the agency said in a commentary in today's Journal of the American Medical Association.
